SCHEMBL10084486

SCHEMBL10084486

Cc1ccc2c(c1)c(=O)n(Cc1ccccc1F)c(=O)n2C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.61
▸ TSHR P16473 3/20 0.61
▸ NPC1 O15118 1/20 0.61
▸ KDM4E B2RXH2 1/20 0.60
▸ LMNA P02545 1/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ TP53 P04637 3/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.50
▸ PARG Q86W56 2/20 0.50
▸ MAPT P10636 2/20 0.48
▸ POLB P06746 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085015 0.86 PCSK9 (0.44) ALDH1A1TSHRNPC1KDM4ELMNA
SCHEMBL10084721 0.82 TP53 (0.63) LMNATP53PARGMAPTPOLB
SCHEMBL10084499 0.80 TP53 (0.49) KDM4ETP53PARGMAPTPOLB
SCHEMBL10084482 0.80 KDM4E (0.57) KDM4ENPSR1TP53PARGPOLB
SCHEMBL10084672 0.79 TP53 (0.62) ALDH1A1TSHRKDM4ELMNAHTT
SCHEMBL10084678 0.79 TP53 (0.53) TSHRKDM4ETP53PARGPOLB
SCHEMBL10084699 0.76 RORA (0.52) KDM4ETP53PARGKMT2AMEN1
SCHEMBL10084710 0.75 MEN1 (0.52) LMNAHTTTP53PARGMAPT
SCHEMBL10085643 0.75 ALDH1A1 (0.45) ALDH1A1TSHRLMNAMAPK1HSD17B10
SCHEMBL10084711 0.74 PARG (0.45) TP53PARGPGRRORARORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 — — US disclosed
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 — — US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 — — US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 — — US disclosed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 — — EP disclosed
EP-2590976-B1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-09-16 — — EP disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 — — US disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 — — US disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 — — US disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 — — US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 — — US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 — — US disclosed
WO-2013102860-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2013-07-11 — — WO disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004732-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH ALDH1A1 2306/4885TSHR 1245/4885NPC1 2974/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 ALDH1A1 2378/4885TSHR 1558/4885NPC1 4542/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH ALDH1A1 2306/4885TSHR 1245/4885NPC1 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback